Iris-fixated phakic IOL could offer options


Santa Ana, CA-Patients who either are severely myopic or fear laser surgery are one step closer to an alternative refractive treatment with the anticipated FDA approval of the Artisan/Verisyse phakic IOL (AMO).

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2023 MJH Life Sciences

All rights reserved.